|
|
||||||||



* Basic Research Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892;
Department of Pediatrics, Medical Academy of Bialystok, Bialystok, Poland;
Duke University Medical Center, Durham, NC 27710; and
Aventis-Pasteur, Toronto, Ontario, Canada
Macaques infected with the SIV strain SIVmac251 develop a disease closely resembling human AIDS characterized by high viremia, progressive loss of CD4+ T cells, occurrence of opportunistic infection, cachexia, and lymphomas. We report in this study that vaccination with the genetically attenuated poxvirus vector expressing the structural Ags of SIVmac (NYVAC-SIV-gag, pol, env) in combination with priming with DNA-SIV-gag, env resulted in significant suppression of viremia within 2 mo after mucosal exposure to the highly pathogenic SIVmac251 in the majority of vaccinated macaques. The control of viremia in these macaques was long lasting and inversely correlated to the level of both pre- and postchallenge Gag-specific lymphoproliferative responses, as well as to the level of total SIV-specific CD4+ T lymphocyte responses at the peak of acute viremia as detected by intracellular cytokine-staining assay. Viremia containment also correlated with the frequency of the immunodominant Gag181189CM9 epitope-specific CD8+ T cells present before the challenge or expanded during acute infection. These data indicate, for the first time, the importance of vaccine-induced CD4+ Th cell responses as an immune correlate of viremia containment. The results presented in this work also further demonstrate the potential of a DNA-prime/attenuated poxvirus-boost vaccine regimen in an animal model that well mirrors human AIDS.
This article has been cited by other articles:
![]() |
L. H. Haut and H. C. J. Ertl Obstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine J. Leukoc. Biol., October 1, 2009; 86(4): 779 - 793. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Rosati, C. Bergamaschi, A. Valentin, V. Kulkarni, R. Jalah, C. Alicea, V. Patel, A. S. von Gegerfelt, D. C. Montefiori, D. J. Venzon, et al. DNA vaccination in rhesus macaques induces potent immune responses and decreases acute and chronic viremia after SIVmac251 challenge PNAS, September 15, 2009; 106(37): 15831 - 15836. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Ourmanov, T. Kuwata, R. Goeken, S. Goldstein, R. Iyengar, A. Buckler-White, B. Lafont, and V. M. Hirsch Improved Survival in Rhesus Macaques Immunized with Modified Vaccinia Virus Ankara Recombinants Expressing Simian Immunodeficiency Virus Envelope Correlates with Reduction in Memory CD4+ T-Cell Loss and Higher Titers of Neutralizing Antibody J. Virol., June 1, 2009; 83(11): 5388 - 5400. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. A. Burgers, G. K. Chege, T. L. Muller, J. H. van Harmelen, G. Khoury, E. G. Shephard, C. M. Gray, C. Williamson, and A.-L. Williamson Broad, high-magnitude and multifunctional CD4+ and CD8+ T-cell responses elicited by a DNA and modified vaccinia Ankara vaccine containing human immunodeficiency virus type 1 subtype C genes in baboons J. Gen. Virol., February 1, 2009; 90(2): 468 - 480. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. C. Zahn, M. D. Rett, B. Korioth-Schmitz, Y. Sun, A. P. Buzby, S. Goldstein, C. R. Brown, R. A. Byrum, G. J. Freeman, N. L. Letvin, et al. Simian Immunodeficiency Virus (SIV)-Specific CD8+ T-Cell Responses in Vervet African Green Monkeys Chronically Infected with SIVagm J. Virol., December 1, 2008; 82(23): 11577 - 11588. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Vaccari, J. Mattapallil, K. Song, W.-P. Tsai, A. Hryniewicz, D. Venzon, M. Zanetti, K. A. Reimann, M. Roederer, and G. Franchini Reduced Protection from Simian Immunodeficiency Virus SIVmac251 Infection Afforded by Memory CD8+ T Cells Induced by Vaccination during CD4+ T-Cell Deficiency J. Virol., October 1, 2008; 82(19): 9629 - 9638. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A. Schoenly and D. B. Weiner Human Immunodeficiency Virus Type 1 Vaccine Development: Recent Advances in the Cytotoxic T-Lymphocyte Platform "Spotty Business" J. Virol., April 1, 2008; 82(7): 3166 - 3180. [Full Text] [PDF] |
||||
![]() |
P. Mooij, S. S. Balla-Jhagjhoorsingh, G. Koopman, N. Beenhakker, P. van Haaften, I. Baak, I. G. Nieuwenhuis, I. Kondova, R. Wagner, H. Wolf, et al. Differential CD4+ versus CD8+ T-Cell Responses Elicited by Different Poxvirus-Based Human Immunodeficiency Virus Type 1 Vaccine Candidates Provide Comparable Efficacies in Primates J. Virol., March 15, 2008; 82(6): 2975 - 2988. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Koopman, D. Mortier, S. Hofman, N. Mathy, M. Koutsoukos, P. Ertl, P. Overend, C. van Wely, L. L. Thomsen, B. Wahren, et al. Immune-response profiles induced by human immunodeficiency virus type 1 vaccine DNA, protein or mixed-modality immunization: increased protection from pathogenic simian human immunodeficiency virus viraemia with protein/DNA combination J. Gen. Virol., February 1, 2008; 89(2): 540 - 5533. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Harari, P.-A. Bart, W. Stohr, G. Tapia, M. Garcia, E. Medjitna-Rais, S. Burnet, C. Cellerai, O. Erlwein, T. Barber, et al. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses J. Exp. Med., January 21, 2008; 205(1): 63 - 77. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kannanganat, B. G. Kapogiannis, C. Ibegbu, L. Chennareddi, P. Goepfert, H. L. Robinson, J. Lennox, and R. R. Amara Human Immunodeficiency Virus Type 1 Controllers but Not Noncontrollers Maintain CD4 T Cells Coexpressing Three Cytokines J. Virol., November 1, 2007; 81(21): 12071 - 12076. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kwissa, R. R. Amara, H. L. Robinson, B. Moss, S. Alkan, A. Jabbar, F. Villinger, and B. Pulendran Adjuvanting a DNA vaccine with a TLR9 ligand plus Flt3 ligand results in enhanced cellular immunity against the simian immunodeficiency virus J. Exp. Med., October 29, 2007; 204(11): 2733 - 2746. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Santra, Y. Sun, J. G. Parvani, V. Philippon, M. S. Wyand, K. Manson, A. Gomez-Yafal, G. Mazzara, D. Panicali, P. D. Markham, et al. Heterologous Prime/Boost Immunization of Rhesus Monkeys by Using Diverse Poxvirus Vectors J. Virol., August 15, 2007; 81(16): 8563 - 8570. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Velu, S. Kannanganat, C. Ibegbu, L. Chennareddi, F. Villinger, G. J. Freeman, R. Ahmed, and R. R. Amara Elevated Expression Levels of Inhibitory Receptor Programmed Death 1 on Simian Immunodeficiency Virus-Specific CD8 T Cells during Chronic Infection but Not after Vaccination J. Virol., June 1, 2007; 81(11): 5819 - 5828. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. A. Wilson, J. Reed, G. S. Napoe, S. Piaskowski, A. Szymanski, J. Furlott, E. J. Gonzalez, L. J. Yant, N. J. Maness, G. E. May, et al. Vaccine-Induced Cellular Immune Responses Reduce Plasma Viral Concentrations after Repeated Low-Dose Challenge with Pathogenic Simian Immunodeficiency Virus SIVmac239. J. Virol., June 1, 2006; 80(12): 5875 - 5885. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. M. Belyakov, V. A. Kuznetsov, B. Kelsall, D. Klinman, M. Moniuszko, M. Lemon, P. D. Markham, R. Pal, J. D. Clements, M. G. Lewis, et al. Impact of vaccine-induced mucosal high-avidity CD8+CTLs in delay of AIDS viral dissemination from mucosa Blood, April 15, 2006; 107(8): 3258 - 3264. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Pal, D. Venzon, S. Santra, V. S. Kalyanaraman, D. C. Montefiori, L. Hocker, L. Hudacik, N. Rose, J. Nacsa, Y. Edghill-Smith, et al. Systemic Immunization with an ALVAC-HIV-1/Protein Boost Vaccine Strategy Protects Rhesus Macaques from CD4+ T-Cell Loss and Reduces both Systemic and Mucosal Simian-Human Immunodeficiency Virus SHIVKU2 RNA Levels. J. Virol., April 1, 2006; 80(8): 3732 - 3742. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Barratt-Boyes, A. C. Soloff, W. Gao, E. Nwanegbo, X. Liu, P. A. Rajakumar, K. N. Brown, P. D. Robbins, M. Murphey-Corb, R. D. Day, et al. Broad cellular immunity with robust memory responses to simian immunodeficiency virus following serial vaccination with adenovirus 5- and 35-based vectors J. Gen. Virol., January 1, 2006; 87(1): 139 - 149. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Hel, W.-P. Tsai, E. Tryniszewska, J. Nacsa, P. D. Markham, M. G. Lewis, G. N. Pavlakis, B. K. Felber, J. Tartaglia, and G. Franchini Improved Vaccine Protection from Simian AIDS by the Addition of Nonstructural Simian Immunodeficiency Virus Genes J. Immunol., January 1, 2006; 176(1): 85 - 96. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. R. Casimiro, F. Wang, W. A. Schleif, X. Liang, Z.-Q. Zhang, T. W. Tobery, M.-E. Davies, A. B. McDermott, D. H. O'Connor, A. Fridman, et al. Attenuation of Simian Immunodeficiency Virus SIVmac239 Infection by Prophylactic Immunization with DNA and Recombinant Adenoviral Vaccine Vectors Expressing Gag J. Virol., December 15, 2005; 79(24): 15547 - 15555. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Vaccari, C. J. Trindade, D. Venzon, M. Zanetti, and G. Franchini Vaccine-Induced CD8+ Central Memory T Cells in Protection from Simian AIDS J. Immunol., September 15, 2005; 175(6): 3502 - 3507. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. G. Fraser, S. R. Leib, B. S. Zhang, R. H. Mealey, W. C. Brown, and T. C. McGuire Lymphocyte Proliferation Responses Induced to Broadly Reactive Th Peptides Did Not Protect against Equine Infectious Anemia Virus Challenge Clin. Vaccine Immunol., August 1, 2005; 12(8): 983 - 993. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Rosati, A. von Gegerfelt, P. Roth, C. Alicea, A. Valentin, M. Robert-Guroff, D. Venzon, D. C. Montefiori, P. Markham, B. K. Felber, et al. DNA Vaccines Expressing Different Forms of Simian Immunodeficiency Virus Antigens Decrease Viremia upon SIVmac251 Challenge J. Virol., July 1, 2005; 79(13): 8480 - 8492. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Nacsa, Y. Edghill-Smith, W.-P. Tsai, D. Venzon, E. Tryniszewska, A. Hryniewicz, M. Moniuszko, A. Kinter, K. A. Smith, and G. Franchini Contrasting Effects of Low-Dose IL-2 on Vaccine-Boosted Simian Immunodeficiency Virus (SIV)-Specific CD4+ and CD8+ T Cells in Macaques Chronically Infected with SIVmac251 J. Immunol., February 15, 2005; 174(4): 1913 - 1921. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Makitalo, P. Lundholm, J. Hinkula, C. Nilsson, K. Karlen, A. Morner, G. Sutter, V. Erfle, J. L. Heeney, B. Wahren, et al. Enhanced cellular immunity and systemic control of SHIV infection by combined parenteral and mucosal administration of a DNA prime MVA boost vaccine regimen J. Gen. Virol., August 1, 2004; 85(8): 2407 - 2419. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. R. M. Negri, S. Baroncelli, S. Catone, A. Comini, Z. Michelini, M. T. Maggiorella, L. Sernicola, F. Crostarosa, R. Belli, M. G. Mancini, et al. Protective efficacy of a multicomponent vector vaccine in cynomolgus monkeys after intrarectal simian immunodeficiency virus challenge J. Gen. Virol., May 1, 2004; 85(5): 1191 - 1201. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. J. Patterson, N. Malkevitch, D. Venzon, J. Pinczewski, V. R. Gomez-Roman, L. Wang, V. S. Kalyanaraman, P. D. Markham, F. A. Robey, and M. Robert-Guroff Protection against Mucosal Simian Immunodeficiency Virus SIVmac251 Challenge by Using Replicating Adenovirus-SIV Multigene Vaccine Priming and Subunit Boosting J. Virol., March 1, 2004; 78(5): 2212 - 2221. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Moniuszko, C. Brown, R. Pal, E. Tryniszewska, W.-P. Tsai, V. M. Hirsch, and G. Franchini High Frequency of Virus-Specific CD8+ T Cells in the Central Nervous System of Macaques Chronically Infected with Simian Immunodeficiency Virus SIVmac251 J. Virol., November 15, 2003; 77(22): 12346 - 12351. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. J. Patterson, N. Malkevitch, J. Pinczewski, D. Venzon, Y. Lou, B. Peng, C. Munch, M. Leonard, E. Richardson, K. Aldrich, et al. Potent, Persistent Induction and Modulation of Cellular Immune Responses in Rhesus Macaques Primed with Ad5hr-Simian Immunodeficiency Virus (SIV) env/rev, gag, and/or nef Vaccines and Boosted with SIV gp120 J. Virol., August 15, 2003; 77(16): 8607 - 8620. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |